Huntington Ingalls Industries Inc vs Tempus AI — how do they compare? Huntington Ingalls Industries Inc trades at $270.08 (market cap $10.64B), while Tempus AI trades at $49.86 (market cap $8.69B). The key difference: Huntington Ingalls Industries Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.04% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| HII | TEM | |
|---|---|---|
Market Cap | $10.64B | $8.69B |
Sector | Technology | Broad Market / Factor |
52-Week High | $453.73 | $103.25 |
52-Week Low | $252.93 | $42.37 |
Enterprise Value | $13.36B | $9.37B |
Dividend Yield | 2.04% | — |
Signals from Pluang's Aura AI — not financial advice
HII trades at $270.04, up 0.34% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows solid fundamentals with a P/E of 17.49 and ROE of 12.2%, supported by three consecutive quarterly earnings beats. Recent news highlights contract wins and shipbuilding milestones, reinforcing its defense sector presence. Cash flow improved to a net positive $49 million in 2026 from a net outflow of $57 million in 2025.
The outlook is cautiously optimistic given analyst consensus targets near $354.50, though technical resistance at $273 poses a near-term hurdle. Risks include execution delays on defense contracts and macroeconomic pressures on government spending. The stock offers value with a below-sector P/S of 0.82, but investors should monitor Q2 2026 earnings due July 30 for margin sustainability.
Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.
The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →